β-lactam/β-lactamase inhibitor combinations: from then to now. (Q38264182)

1 September 2017

1 reference

title

β-lactam/β-lactamase inhibitor combinations: from then to now. (English)

1 reference

1 September 2017

1 reference

ChEBI release 2020-05-28

Kimberly A Toussaint

1

1 reference

1 September 2017

Jason C Gallagher

series ordinal

2

1 reference

1 September 2017

language of work or name

English

0 references

publication date

31 October 2014

1 reference

Annals of Pharmacotherapy

1 September 2017

1 reference

1 September 2017

49

1 reference

1 September 2017

1

1 reference

1 September 2017

86-98

1 reference

Beta-lactam antibiotic resistance: a current structural perspective.

1 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Determinants of the activity of beta-lactamase inhibitor combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Beta-lactamase inhibitors from laboratory to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Extended-spectrum plasmid-mediated beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

21 January 2018

The new beta-lactamases.

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Resistance in gram-negative bacteria: enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Class D β-lactamases: a reappraisal after five decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

A functional classification scheme for beta-lactamases and its correlation with molecular structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Updated functional classification of beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Epidemiology of antibiotic resistance in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Beta-lactamase-mediated resistance and opportunities for its control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Carbapenemases: the versatile beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Zinc and antibiotic resistance: metallo-beta-lactamases and their synthetic analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Efficacy of calcium-EDTA as an inhibitor for metallo-β-lactamase in a mouse model of Pseudomonas aeruginosa pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

A comparative study of class-D beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Diversity, epidemiology, and genetics of class D beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Three decades of beta-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta-lactamase: Raman crystallographic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

New β-lactam-β-lactamase inhibitor combinations in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC -Lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Kinetics of avibactam inhibition against Class A, C, and D β-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized stud

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isola

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

The inoculum effect: fact or artifact?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

Increased waterborne blaNDM-1 resistance gene abundances associated with seasonal human pilgrimages to the upper ganges river

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014556652

21 January 2018

Identifiers

DOI

10.1177/1060028014556652

1 reference

release_3hfvidpi2vdnplwhqergg3cose

1 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3hfvidpi2vdnplwhqergg3cose

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference